Skip to main content

Table 1 Normalized gene expression for each of the 150 PDX samples, classified by tumor type (noted in bold)

From: Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings

Sample nature Derived from primary tumor or metastatis % of mouse cells PECAM1 ENG VEGFR1 VEGFR2 VEGFA % of mVegfavs human + mouse VEGFA transcripts
    Hs Mm Hs Mm Hs Mm Hs Mm Hs Mm  
Pure human control   0% 1265 0 796 0 2610 0 157 0 287 0  
Pure mouse control   100% 0 1176 0 736 0 303 0 879 0 790  
Colorectal carcinoma PDX              
CRC#1 Primary 11% 0 894 2 492 23 453 0 405 4010 212 5%
CRC#2 Primary 5% 0 917 3 398 9 383 0 309 4912 51 1%
CRC#3 Metastasis 21% 1 2380 34 893 14 843 0 803 4642 628 12%
CRC#4 Primary 17% 0 836 <1 285 0 368 0 299 2876 302 10%
CRC#5 Metastasis 8% 0 813 0 492 3 337 0 374 3552 109 3%
CRC#6 Primary 9% 46 458 217 326 77 196 <1 176 1866 84 4%
CRC#7 Metastasis 8% 17 553 27 272 65 292 0 210 5230 251 5%
CRC#8 Primary 14% 0 1193 469 614 3 349 0 689 2999 92 3%
CRC#9 Primary 8% 0 967 8 550 3 475 0 379 7973 204 2%
CRC#10 Primary 10% 0 733 <1 409 176 246 0 284 3463 124 3%
CRC#11 Metastasis 9% 1 1083 <1 481 300 567 0 410 5461 135 2%
CRC#12 Metastasis 4% 48 479 0 182 26 274 0 230 4937 106 2%
CRC#13 Metastasis 4% 3 356 5 135 289 163 0 168 3606 145 4%
CRC#14 Primary 2% <1 260 7 139 305 119 0 143 5085 76 1%
CRC#15 Primary 17% <1 1287 <1 715 51 530 0 419 6541 311 5%
CRC#16 Metastasis 5% <1 477 44 237 89 197 0 219 3406 196 5%
CRC#17 Primary 17% 21 1067 49 539 42 382 0 323 3674 555 13%
CRC#18 Primary 14% 4 1078 81 550 33 370 <1 356 2016 262 12%
CRC#19 Primary 4% 3 288 <1 162 <1 120 0 135 4258 111 3%
CRC#20 Metastasis 22% 4 1580 19 754 10 584 <1 684 5604 391 7%
CRC#21 Metastasis 17% 10 1336 373 749 10 656 0 639 4894 432 8%
CRC#22 Primary 18% 0 2315 322 1081 32 908 0 1262 4671 1244 21%
CRC#23 Metastasis 8% 0 446 407 406 42 202 0 173 2360 155 6%
CRC#24 Primary 12% 0 981 5 581 13 508 0 331 4773 233 5%
CRC#25 Primary 5% 0 622 36 329 0 246 0 285 2643 68 3%
CRC#26 Primary 11% 0 1245 569 480 112 375 0 296 3607 237 6%
CRC#27 Primary 14% 4 1789 3 895 83 682 0 581 3101 891 22%
CRC#28 Carcinosis 5% 3 526 1 326 1 215 0 268 2545 29 1%
CRC#29 Primary 11% 5 1000 2 541 0 364 0 344 3172 391 11%
CRC#30 Primary 7% 0 753 11 332 22 282 0 258 2247 231 9%
CRC#31 Metastasis 10% <1 629 1 294 29 241 0 216 2896 210 7%
CRC#32 Primary 16% 0 1073 304 556 28 357 0 469 1731 166 9%
CRC#33 Primary 7% 4 563 <1 277 7 202 0 218 1253 129 9%
CRC#34 Primary 13% 2 749 379 530 15 306 0 390 4293 157 4%
CRC#35 Primary 9% 0 958 3 484 9 329 0 318 2206 212 9%
CRC#36 Primary 21% 1 991 0 504 32 388 <1 436 3296 140 4%
CRC#37 Primary 19% 6 1978 16 840 10 391 0 668 2692 182 6%
CRC#38 Primary 8% 2 1114 8 446 2 320 0 367 1889 218 10%
CRC#39 Metastasis 12% 0 1156 478 523 40 366 0 418 4034 214 5%
CRC#40 Primary 10% <1 547 94 356 49 199 0 242 1848 142 7%
CRC#41 Carcinosis 16% 0 1552 3 762 7 325 0 457 918 228 20%
CRC#42 Primary 31% 0 1786 <1 922 94 447 0 599 2710 493 15%
CRC#43 Primary 10% 0 1024 75 459 249 358 2 431 4126 272 6%
CRC#44 Carcinosis 15% <1 938 159 565 1 285 0 364 2523 269 10%
CRC#45 Primary 12% 1654 807 512 388 9 215 1 332 969 124 11%
CRC#46 Primary 3% <1 412 3 158 2 139 0 168 1865 61 3%
CRC#47 Metastasis 6% 0 521 2 252 <1 173 0 195 1662 68 4%
CRC#48 Carcinosis 10% 0 843 <1 417 0 252 0 252 1705 227 12%
CRC#49 Metastasis 6% 1 379 426 274 11 248 0 267 4587 149 3%
CRC#50 Metastasis 18% 31 1697 0 690 23 485 0 421 5271 299 5%
CRC#51 Primary 23% 0 1294 2 662 67 476 0 375 6660 583 8%
CRC#52 Primary 38% 14 3265 398 1126 640 736 0 836 7517 953 11%
CRC#53 Metastasis 19% 0 1657 0 566 15 430 0 430 4014 209 5%
Median   10.6% 0.7 958 7 484 22 349 0 344 3463 210 6%
Ovarian carcinoma PDX              
OVC#1 Metastasis 28% 42 2575 0 1498 89 1191 159 867 10390 459 4%
OVC#2 Metastasis 5% 4 565 99 350 2 439 34 259 6391 88 1%
OVC#3 Metastasis 21% 1 1427 304 809 69 406 <1 583 3133 710 18%
OVC#4 Primary 6% 26 709 9 474 0 259 4 272 1528 144 9%
OVC#5 Primary 7% 16 974 81 807 0 802 45 525 14226 95 1%
OVC#6 Primary 12% 3 2052 97 593 19 734 101 528 2628 427 14%
OVC#7 Primary 8% 0 762 4 470 0 270 32 278 6156 266 4%
OVC#8 Primary 3% 2 219 30 119 6 88.8 3 59.2 652 37 5%
OVC#9 Primary 8% 5 1795 2 674 3 518 5 372 2981 184 6%
OVC#10 Primary 4% 1 444 16 288 0 204 22 141 2812 52 2%
OVC#11 Primary 20% 24 1586 54 1036 0 482 2 648 2781 493 15%
OVC#12 Primary 13% 3 877 177 487 0 259 12 285 1720 127 7%
OVC#13 Primary 3% 17 550 207 263 2 196 <1 224 1134 16 1%
OVC#14 Primary 5% 0 332 <1 255 21 238 <1 164 19239 62 0%
Median   7% 3.7 819 42 480 2 338 9 281 2896 136 5%
Glioblastoma PDX              
GBM#1 Primary 8% 22 712 2051 457 378 559 8 186 18822 241 1%
GBM#2 Primary 13% 1 1351 1143 819 0 799 378 328 17084 296 2%
GBM#3 Primary 13% 1 2372 422 1184 0 1325 0 1237 8452 131 2%
GBM#4 Primary 5% 55 870 321 328 0 503 0 372 5923 78 1%
GBM#5 Primary 15% 0 2600 268 1389 28 1361 294 1413 15443 100 1%
Median   13% 1.4 1351 422 819 0 799 8 372 15443 131 1%
Breast cancer carcinoma PDX              
BC#1 Primary 2% <1 222 204 113 3 89.4 2 80.7 637 114 15%
BC#2 Primary 8% 0 666 177 335 19 289 0 162 2997 310 9%
BC#3 Metastasis 10% 0 679 286 447 5 539 36 259 4961 334 6%
BC#4 Primary 15% 46 803 91 498 5 366 0 222 3547 447 11%
BC#5 Primary 1% <1 116 0 61.9 33 89.1 4 31.9 15066 77 1%
BC#6 Metastasis 15% 2 1351 289 634 29 719 150 439 17360 357 2%
BC#7 Primary 22% 8 1908 442 887 0 1370 0 739 27659 365 1%
BC#8 Primary 6% 1 810 149 412 18 327 9 280 8360 160 2%
BC#9 Metastasis 10% 0 713 6 322 13 420 0 279 1020 294 22%
BC#10 Primary 6% 3 370 460 233 0 325 17 134 7447 154 2%
BC#11 Primary 6% 6 993 347 403 29 461 68 325 14282 256 2%
BC#12 Primary 8% 6 1005 466 543 28 664 3 391 25794 363 1%
BC#13 Primary 7% 0 575 92 256 8 266 15 189 6174 132 2%
BC#14 Primary 8% 654 745 45 413 0 279 2 253 3294 71 2%
BC#15 Metastasis 11% 4 912 50 461 1 311 0 286 3458 186 5%
BC#16 Primary 2% 0 199 188 94.6 4 73.6 2 69.7 610 100 14%
BC#17 Primary 4% 13 413 346 134 66 173 32 101 2131 197 8%
BC#18 Primary 10% <1 1545 168 743 3 788 11 382 6550 167 2%
BC#19 Metastasis 16% <1 2304 167 1188 5 1049 10 771 6004 280 4%
BC#20 Primary 17% 0 1967 340 959 1 709 20 634 11533 357 3%
BC#21 Primary 9% 0 730 334 332 2 476 91 202 8166 520 6%
BC#22 Primary 6% 0 598 451 222 10 334 90 124 5088 264 5%
BC#23 Primary 4% 0 377 331 179 2 195 19 83.3 1742 51 3%
BC#24 Primary 22% 1 1128 858 982 79 999 <1 495 21363 668 3%
BC#25 Primary 10% 0 1165 666 573 94 627 12 474 14542 244 2%
BC#26 Primary 10% 0 1446 429 572 0 685 230 510 5771 257 4%
BC#27 Primary 14% 2 880 4 452 94 415 <1 222 1505 299 17%
BC#28 Primary 5% <1 182 91 113 7 119 6 80.3 1221 50 4%
BC#29 Primary 9% <1 656 530 469 32 532 9 473 50360 255 1%
BC#30 Primary 7% 3 823 94 341 247 403 34 244 9097 373 4%
BC#31 Primary 4% 0 345 166 216 0 161 3 145 1085 79 7%
BC#32 Primary 7% <1 629 13 276 4 237 19 194 1544 198 11%
BC#33 Primary 9% <1 725 397 428 232 549 6 231 5414 144 3%
BC#34 Primary 14% 5 1061 245 557 0 457 0 308 3866 176 4%
BC#35 Primary 5% 2 484 103 358 3 506 50 185 23896 360 1%
BC#36 Primary 13% 0 1085 221 544 0 333 13 347 1153 231 17%
BC#37 Primary 4% 0 376 193 149 <1 144 13 120 1081 289 21%
BC#38 Primary 6% 2 776 90 415 8 326 12 281 4683 178 4%
BC#39 Primary 14% 0 961 5 731 83 691 4 606 4829 152 3%
Median   7.9% 0.7 745 193 413 5 403 10 253 5088 244 4%
Cutaneous melanoma PDX              
CM#1 Metastasis 11% 0 1725 2985 825 0 953 83 1026 10386 1401 12%
CM#2 Metastasis 7% 27 544 1391 426 768 360 0 184 10696 315 3%
CM#3 Metastasis 4% 1 282 257 180 0 122 1 155 599 102 14%
CM#4 Primary 20% 0 3306 784 1178 427 883 38 836 9188 718 7%
CM#5 Metastasis 8% 9 936 872 363 15 587 0 289 5590 201 3%
CM#6 Metastasis 3% <1 342 648 196 6 188 5 236 960 23 2%
CM#7 Metastasis 1% 2 176 382 83.6 2 135 <1 84.3 5962 37 1%
CM#8 Primary 10% 9 4760 876 705 0 2230 5 841 16732 239 1%
CM#9 Metastasis 1% 0 118 284 61.6 20 125 14 73.6 3704 24 1%
CM#10 Primary 10% 0 876 756 300 0 248 279 285 387 126 25%
CM#11 Metastasis 8% 2 641 1102 427 0 355 1 309 8837 266 3%
CM#12 Primary 5% 0 530 112 186 0 440 0 423 683 26 4%
CM#13 Metastasis 2% <1 243 145 101 <1 116 1 82.2 466 31 6%
Median   7.1% 0.9 544 756 300 0.8 355 1 285 5590 126 3%
Renal cell carcinoma PDX              
RCC#1 Primary 17% 0 1179 569 1002 0 680 2 473 19769 1513 7%
RCC#2 Primary 12% 0 3362 16 1929 0 1934 0 3043 27096 54 0%
RCC#3 Primary 27% 0 5431 411 2376 0 1866 0 1974 25792 211 1%
RCC#4 Metastasis 11% 120 2117 256 1430 4 1512 0 1337 13968 89 1%
RCC#5 Primary 16% 5 2906 33 1942 3 1624 0 2102 25817 87 0%
RCC#6 Primary 1% 1 341 2 125 2 157 47 119 609 13 2%
RCC#7 Primary 21% 0 768 549 1908 0 1292 0 1324 27232 157 1%
RCC#8 Metastasis 17% 1 842 410 778 0 466 0 286 1756 930 35%
RCC#9 Metastasis 13% 17 2024 230 1258 3 827 1 904 37839 55 0%
RCC#10 Primary 11% 0 2010 856 1359 0 1070 2 672 37217 83 0%
RCC#11 Primary 5% 2 597 907 350 0 487 0 253 5091 136 3%
RCC#12 Metastasis 14% 0 2546 257 1132 0 871 0 1040 16952 61 0%
RCC#13 Primary 21% 0 4963 38 3466 0 3281 0 3966 30645 155 1%
RCC#14 Primary 6% 330 1338 364 602 0 661 2 343 26952 52 0%
RCC#15 Primary 6% 77 565 1036 293 0 368 0 291 2210 59 3%
Median   12.9% 1.2 2010 364 1258 0 871 0 904 25792 87 1%
Lung carcinoma PDX              
Small cell lung carcinoma              
SCLC#1 Primary 8% 0 1030 3 387 0 250 0 196 419 43 9%
SCLC#2 Primary 3% 2 632 0 238 5 189 0 185 1300 52 4%
SCLC#3 Primary 4% 4 591 0 259 1 232 2 232 1117 49 4%
SCLC#4 Primary 3% 7 395 0 222 0 166 0 162 1498 46 3%
SCLC#5 Metastasis 2% 0 309 1 153 0 160 2 122 893 56 6%
SCLC#6 Primary 7% 2 670 9 221 471 208 72 192 954 86 8%
Median   3.3% 1.7 612 0 230 1 198 1 189 1035 51 5%
Non small cell lung carcinoma             
NSCLC#1 Primary 28% 3 1969 61 941 2 1145 14 637 18440 794 4%
NSCLC#2 Primary 8% 0 1270 0 611 0 511 335 639 5911 98 2%
NSCLC#3 Primary 22% 95 1590 31 1438 124 961 930 669 18346 429 2%
NSCLC#4 Primary 5% 2 686 5 339 4 212 59 221 875 85 9%
NSCLC#5 Primary 20% 3 1363 667 1387 184 896 3106 652 10612 688 6%
Median   20% 2.7 1363 31 941 4 896 335 639 10612 429 4%